Home › Lung Cancer › NCT05049837
PROSPECT - Profiling of Resistance Patterns & Oncogenic Signaling Pathways in Evaluation of Cancers of the Thorax and Therapeutic Target Identification
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: Eligible patients should be ones who have stage I-IIIA non-small cell lung cancer (NSCLC) and undergo surgical resection with or without neoadjuvant chemotherapy as part of standard treatment, and have a information of demographics, smoking history, preoperative clinical data, and follow -up data including adjuvant therapy, relapse, and treatment at relapse. We will include the three major NSCLC histologic subtypes, adenocarcinoma, squamous cell carcinoma, and large cell carcinoma - Exclusion Criteria: None
About the study
In this Project, we will use therapeutic target -focused (TTF) profiling, genome-wide mRNA profiling and assessments of tumor phosphopeptides and DNA that are shed into the blood stream to define how various molecular factors alone and in combination relate to resistance to therapy, to prognosis, and to metastatic patterns at relapse. We will examine how the presence of factors that drive cell growth, antagonize apoptosis, or confer resistance in other ways may counter the effect of systemic therapies and/or promote rapid tumor recurrence. In this way, we will identify new, previously unappreciated potential therapeutic targets while also identifying which targets are most likely to increase resistance to therapy and worsen prognosis.
What is being tested
- Group Specific Aim 1 (other)
- Group Specific Aim 2 (other)
- Group Specific Aim 3 (other)
- Group Specific Aim 4 (other)
- Group Specific Aim 5 (other)
- Group Specific Aim 6 (other)
Sponsor: M.D. Anderson Cancer Center · Participants: 7,200 · Started: Apr 25, 2007
Contact the study team
- Luisa M Solis Soto, MD · Phone: 832-794-1469
Official record on ClinicalTrials.gov — NCT05049837
Locations in the U.S.
| Texas | M D Anderson Caner Center, Houston |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.